| Hans-Günter Meyer-Thompson | Buprenorphin
Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder
Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder
Lund, Sweden. Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee jointly voted 17-3 recommending approval of CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder (OUD). (Camurus, 01.11.2017, media -> press releases -> archive)